Duchenne muscular dystrophy and related dystrophinopathies: developing drugs for treatment
- Series Title(s):
- Guidance for industry
United States. Department of Health and Human Services, issuing body.
United States. Food and Drug Administration, issuing body.
Center for Biologics Evaluation and Research (U.S.), issuing body.
Center for Drug Evaluation and Research (U.S.), issuing body.
- Silver Spring, MD : Center for Drug Evaluation and Research, February 2018
- Clinical Trials as Topic -- standards Drug Evaluation -- standards Muscular Dystrophies -- drug therapy Muscular Dystrophy, Duchenne -- drug therapy Drug Labeling -- standards Drugs, Investigational Research Design Humans United States United States. Department of Health and Human Services. United States. Food and Drug Administration.
- Guideline Technical Report
- The National Library of Medicine believes this item to be in the public domain. (More information)
- 1 online resource (1 PDF file (13 pages)).
- NLM Unique ID:
- 101734048 (See catalog record)